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Background. The role of coffee intake as a risk factor for coronary heart disease (CHD) has been debated for decades. We
examined whether the relationship between coffee intake and incidence of CHD events is dependent on the metabolism of
circulating catecholamines, as determined by functional polymorphism of the catechol-O-methyltransferase (COMT) gene.
Methodology/Principal Findings. In a cohort of 773 men who were 42 to 60 years old and free of symptomatic CHD at
baseline in 1984–89, 78 participants experienced an acute coronary event during an average follow-up of 13 years. In logistic
regression adjusting for age, smoking, family history of CHD, vitamin C deficiency, blood pressure, plasma cholesterol
concentration, and diabetes, the odds ratio (90% confidence interval) comparing heavy coffee drinkers with the low activity
COMT genotype with those with the high activity or heterozygotic genotypes was 3.2 (1.2–8.4). Urinary adrenaline excretion
increased with increasing coffee intake, being over two-fold in heavy drinkers compared with nondrinkers (p=0.008 for trend).
Conclusions/Significance. Heavy coffee consumption increases the incidence of acute coronary events in men with low but
not high COMT activity. Further studies are required to determine to which extent circulating catecholamines mediate the
relationship between coffee intake and CHD.
Citation: Happonen P, Voutilainen S, Tuomainen T-P, Salonen JT (2006) Catechol-O-Methyltransferase Gene Polymorphism Modifies the Effect of
Coffee Intake on Incidence of Acute Coronary Events. PLoS ONE 1(1): e117. doi:10.1371/journal.pone.0000117
INTRODUCTION
Despite decades of research, controversy persists regarding the
effects of coffee consumption on cardiovascular health [1,2]. Coffee
drinkingisaprevalenthabitworldwideandoneconstituent ofcoffee,
caffeine, is probably the most frequently ingested pharmacologically
active substance in the world [3]. Many of the known or suspected
cardiovascular effects of coffee have been attributed to caffeine, but
coffee is a mixture of hundreds of chemical substances, many of
which have been shown to be pharmacologically active. For
example, cafestol increases serum LDL cholesterol concentrations
[4], caffeic acid and other polyphenols in coffee are potent
antioxidants [5], and even decaffeinated coffee acutely increases
blood pressure and muscle sympathetic nerve activity [6].
We have recently reported a U-shaped dose–response relation-
ship between intake of caffeine-containing coffee and incidence of
acute coronary events [7]; similar findings have been reported
from at least two other studies [8,9]. In order to gain further
insight into the pathogenetic mechanisms, we hypothesized that
the increased risk in heavy drinkers of caffeine-containing coffee is,
at least partly, mediated by increased circulating catecholamine
activity. Caffeine is a potent stimulator of plasma renin activity
and adrenomedullary secretion; acute ingestion results in sub-
stantial increases in plasma concentrations of adrenaline and
noradrenaline [10]. Tolerance to these acute humoral effects may
develop in the course of one to four days of habitual consumption
[11], but is not complete [12] and may be lost after abstinence for
as little as 12 hours [13,14].
To test this hypothesis, we examined whether the functional
polymorphism of the catechol-O-methyltransferase (COMT) gene,
resulting in several-fold differences in the metabolism of circulating
catecholamines, modifies the effect of heavy consumption of
caffeine-containing coffee on the risk of acute coronary events in
a cohort of middle-aged eastern Finnish men initially free from
symptomatic CHD.
METHODS
Study design and population
The Kuopio Ischaemic Heart Disease Risk Factor Study is
a population-based prospective follow-up study of 2682 men aged
42, 48, 54, or 60 years at the baseline examination carried out in
1984–89 [15]. The study was approved by the University of
Kuopio Research Ethics Committee; all participants gave written
informed consent. The study population was recruited in two
cohorts. The present analysis is based on the latter cohort of 1516
men enrolled between 1986 and 1989. After exclusion of 353 men
with prevalent CHD at baseline, as defined earlier [16], data on
coffee consumption and smoking, as well as a deoxyribonucleic
acid (DNA) sample, were available for 773 men.
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COMT polymorphism is generated by the presence of guanine or
adenine at nucleotide 475 encoding a valine or methionine at
codon 158 and is recognized by the heat-shock protein 92 II
restriction endonuclease. The polymorphism results in three
different genotypes: homozygous for the low activity allele
(methionine/methionine; LL genotype), homozygous for the high
activity allele (valine/valine; HH genotype), and heterozygous
(methionine/valine; LH genotype).
DNA was extracted from 10 mL of ethylenediaminetetraacetic-
acid-anticoagulated venous blood using standard salting-out or
phenol-chloroform assays. COMT genotypes were determined by
restriction fragment length polymorphism analysis from the DNA
by an investigator unaware of the phenotype. A 179 base-pair
polymerase chain reaction product was generated using the
forward 59-CTG CTG GAG CTG GGG GCC GAC-39 and
reverse 59-AGG TCT TCA GGA ATG C-39 primers. The
polymerase chain reaction product (5 mL) was treated with two
units of heat-shock protein 92 II for 16 hours at 37uC and then
analyzed by 2% agarose gel electrophoresis. The diagnostic bands
were 179 (valine) and 139 (methionine).
Assessment of Coffee Intake and Diet
Consumption of foods and beverages was assessed with an
instructed and interview-checked 4-day food recording by house-
hold measures, including cups of coffee and tea [17]. The volume
of the cup mainly used by each participant was estimated by
showing photographs of four different cup sizes generally avail-
able. Dietary intake of foods and nutrients was calculated using
NUTRICA software (National Public Health Institute, Turku,
Finland).
Measurement of Covariates and Catecholamine
Excretion
The examination protocol and measurements have been described
previously [15,16]. Briefly, a participant was defined a current
smoker, if he had ever smoked on a regular basis and had smoked
within the past 30 days. The lifelong exposure to smoking was
estimated as the product of years smoked and the number of
cigarettes, cigars, and pipefuls smoked at the baseline examination.
Diabetes was defined as self-reported diabetes mellitus or fasting
blood glucose of 6.1 mM or more. Assessment of alcohol con-
sumption, serum lipids, blood pressure, and body mass index [16],
conditioning leisure-time physical activity [18], waist–hip ratio
[19], and plasma vitamin C concentration [20] was carried out as
described previously.
Urinary adrenaline and noradrenaline were purified with com-
mercial phenylboronic acid columns and analyzed under isocratic
conditions by reverse-phase liquid chromatography (for a detailed
description, see [21]).
Ascertainment of CHD Events
The collection of data on and classification of possible acute
myocardial infarction and coronary death (here referred to as
‘‘acute coronary events’’) until the end of 1992 is previously
described [16,22]. From 1993, data on acute coronary events were
obtained by computer linkage to the national hospital discharge
registry; diagnostic information was collected from the hospitals
and classified using identical diagnostic criteria. There were no
losses to follow-up. In case of multiple events in the same
participant, the first event was considered the endpoint.
Statistical Analysis
All analyses were performed with SPSS version 11.5 (SPSS Inc.,
Chicago, IL). Average daily coffee intake was divided into four
categories: 0 (non-drinkers), 1 to 375 mL (light drinkers), 376 to
813 mL (moderate drinkers), and 814 mL and over (heavy
drinkers). (Since the coffee content in the most common cup size
in this population is 125 mL, these coffee intake categories
approximately correspond to less than 3 cups, 3 to 6.5 cups, and
more than 6.5 cups per day, respectively.) To evaluate biologic
interaction (departures from additivity), a single composite variable
with six joint-exposure categories was created; the COMT LH and
LL genotypes were combined into a single category and coffee
non-drinkers were combined with light drinkers. Logistic re-
gression was used to assess the association between the composite
coffee intake–COMT variable and acute coronary events; heavy
coffee drinkers with either the HH or LH genotype were used as
the reference category. Continuous covariates without a meaning-
ful zero value were centered around their respective means.
Statistical inference was based on 90% Wald confidence intervals
or two-sided p-values.
In a subgroup of 258 participants with urinary catecholamine
measurements, we performed a supplemental linear regression
analysis of urinary adrenaline and noradrenaline excretion in
categories of coffee intake. Data on catecholamine excretion
according to COMT genotype were not available.
RESULTS
Baseline characteristics according to coffee intake are shown in
Table 1 and according to COMT genotype in Table 2. In com-
parison with light to moderate drinkers, heavy coffee drinkers were
more likely to be smokers, had a higher energy and saturated fat
intake but lower leisure-time physical activity level, and their LDL
cholesterol concentrations were higher. Compared with nondrin-
kers, coffee drinkers were more likely to be smokers and to have
a family history of CHD; had lower leisure-time physical activity
levels, a higher body mass index and waist–hip ratio, higher
systolic and diastolic blood pressure; and higher LDL cholesterol
concentration. Participants with the COMT HH genotype were
less likely to be diabetic and had lower levels of leisure-time
physical activity than those with the other two genotypes; systolic
blood pressure was marginally higher in the LL genotype.
In the supplemental analysis of urinary catecholamine excretion
among 258 participants, the amount of adrenaline excreted was
over two-fold in the heavy coffee intake category compared with
non-drinkers (p=0.008 for trend); for noradrenaline, the re-
spective difference was 30% (p=0.039 for trend).
A total of 78 acute coronary events were identified during an
average follow-up of 13 years. The cumulative incidence rate in
other categories of coffee intake was relatively stable (around 10%)
but clearly increased in heavy drinkers with the COMT LL
genotype (Table 3). After adjustment for age, packyears of
smoking, family history of CHD, and vitamin C deficiency, the
odds ratio (90% confidence interval) comparing heavy drinkers in
the LL genotype with heavy drinkers in the other two genotypes
was 3.25 (1.29–8.16). Further adjustment for systolic blood
pressure, serum LDL and HDL cholesterol concentration, and
diabetes minimally decreased the odds ratio estimate to 3.21
(1.22–8.42). In the combined HH or LH category, the adjusted
odds ratios for light and moderate coffee drinkers were 1.45 (0.64–
3.27) and 1.39 (0.67–2.88), respectively; the corresponding odds
ratios in the LL genotype were 1.73 (0.68–4.42) and 1.31 (0.58–
2.99), using the heavy drinkers with either the COMT HH or LH
genotype as the reference category (Figure 1). Adjustment for
COMT, Coffee Intake and CHD
PLoS ONE | www.plosone.org 2 December 2006 | Issue 1 | e117Table 1. Characteristics of the study participants, according to their average daily consumption of coffee.*
..................................................................................................................................................
Coffee intake category{
Total group No coffee Light Moderate Heavy
n 773 28 183 430 132
Median coffee intake, mL 0 269 579 938
Age, y 51.266.6 49.565.4 52.266.5 51.266.7 50.266.7
Current smoker, % 30 14 27 27 49
Physical activity, kcal/day 1416154 1846223 1366145 1496159 1176125
Family history of CHD, % 49 36 47 51 46
Diabetes, % 4.0 3.6 4.4 3.7 4.6
Alcohol intake, g per week 766118 1026283 826126 726101 72697
Saturated fat intake, % energy 19.064.2 17.365.5 18.864.3 18.863.9 20.264.3
Daily total energy intake, MJ 10.762.7 11.162.8 9.862.3 10.762.6 11.663.1
Plasma vitamin C concentration, mmol/L 47.7623.3 51.3624.2 48.5623.2 48.5623.1 43.6623.7
Body mass index, kg/m
2 26.663.3 25.764.0 26.863.6 26.763.3 26.463.1
Waist–hip ratio .936.06 .916.06 .946.05 .936.06 .946.08
Systolic blood pressure, mmHg 132.5615.7 125.6619.5 134.4616.9 132.4614.4 132.0617.0
Diastolic blood pressure, mmHg 88.0610.1 83.3611.5 88.9610.3 88.169.8 87.0610.2
Serum LDL cholesterol, mmol/L 3.836.93 3.606.91 3.816.96 3.806.92 4.006.91
Serum HDL cholesterol, mmol/L 1.316.29 1.336.32 1.326.31 1.306.28 1.306.29
COMT LL genotype, % 29 25 29 30 27
*Plus–minus values are means6SD.
{Light, 1–375 mL; moderate, 376–813 mL; and heavy, more than 814 mL.
doi:10.1371/journal.pone.0000117.t001
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Table 2. Characteristics of the study participants, according to their COMT genotype.*
..................................................................................................................................................
COMT genotype{
Total group HH LH LL
n 773 169 378 226
Coffee intake, mL 5556295 5826305 5396298 5616282
Age, y 51.266.6 51.166.7 50.866.4 51.867.0
Current smoker, % 30 31 30 31
Physical activity, kcal/day 1416154 1206117 1416155 1586173
Family history of CHD, % 49 54 46 49
Diabetes, % 4.0 1.8 3.7 6.2
Alcohol intake, g per week 766118 786113 66691 906155
Saturated fat intake, % energy 19.064.2 19.564.0 18.964.2 18.964.2
Daily total energy intake, MJ 10.762.7 10.962.6 10.762.8 10.562.6
Plasma vitamin C concentration, mmol/L 52.0622.0 52.4622.7 52.5622.8 51.0620.2
Body mass index, kg/m
2 26.663.3 26.563.2 26.363.2 27.163.6
Waist–hip ratio .936.06 .936.06 .936.07 .946.05
Systolic blood pressure, mmHg 132.5615.7 131.1615.0 132.5615.6 133.5616.4
Diastolic blood pressure, mmHg 88.0610.1 88.1610.1 88.0610.3 87.869.8
Serum LDL cholesterol, mmol/L 3.836.93 3.846.84 3.816.94 3.866.98
Serum HDL cholesterol, mmol/L 1.316.29 1.326.28 1.306.29 1.306.31
*Plus–minus values are means6SD.
{HH, homozygous for high COMT activity allele; LH, heterozygous; and LL, homozygous for low COMT activity allele.
doi:10.1371/journal.pone.0000117.t002
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COMT, Coffee Intake and CHD
PLoS ONE | www.plosone.org 3 December 2006 | Issue 1 | e117physical activity; intake of alcohol, saturated fat, or total energy; or
body mass index and waist–hip ratio did not change the odds ratio
estimates appreciably or contribute to model fit.
DISCUSSION
In this population-based cohort of middle-aged men initially free
from symptomatic CHD followed-up for an average of 13 years,
we found a relationship between consumption of caffeine-
containing coffee and the incidence of fatal or nonfatal CHD
events that is highly dependent on COMT genotype. In men who
were either homozygous for the high COMT activity allele or
heterozygotes, heavy coffee intake did not increase the incidence
of acute coronary events. In men who were homozygous for the
low-activity COMT allele, however, heavy coffee intake was
associated with a considerably higher incidence of acute coronary
events. The relative excess in CHD incidence in the low-activity
genotype was over two-fold among drinkers of more than 6.5 cups
of coffee per day, after adjustment for age, smoking, family history
of CHD, plasma vitamin C concentration, systolic blood pressure,
serum LDL and HDL cholesterol concentration, and diabetes.
We are not aware of any previous studies that have addressed
the modification of the coffee–CHD relationship by COMT
activity. Tens of studies investigating the relationship between
coffee consumption and the incidence of CHD have been carried
out, but the results remain inconsistent. Several large studies
carried out in the United States have found no appreciable
increase in CHD risk with increasing coffee consumption [23–25].
Two earlier U.S. studies, however, reported a two-fold risk of
myocardial infarction [26] or CHD [27] in men drinking 5 cups of
coffee or more; the risk was three-fold among those drinking 10
cups or more [26], compared with non-drinkers.
The findings have been in part dependent on the type of study:
case–control studies have generally reported higher effect estimates
than cohort studies [1]. In studies published more recently, the
discrepancy between cohort and case–control studies persists [28–
30]. As an explanation for the discrepancy between study types it
has been suggested that coffee drinking has mainly acute or short-
term effects, which cohort studies with extended follow-up periods
would be likely to miss [27]. In general, the inconsistency between
studies has been attributed to differences in coffee brews, study
populations, range of coffee intake, confounding by smoking or
other lifestyle factors, and measurement inaccuracy.
Two recent studies have observed a U-shaped pattern between
coffee consumption and CHD incidence [7,9], suggesting that the
relationship between coffee intake and CHD is more complex than
previously recognized and offering yet another potential explana-
tion for the contradictory findings in the literature. In both studies,
the J- or U-shaped association persisted after adjustment for
known risk factors for CHD, such as hypertension, high LDL
cholesterol concentration, and diabetes, which could partially
mediate the effects of coffee intake. In our previous study [7], the
association was also independent of the brewing method of coffee,
which has long been offered as a likely explanation for increased
risk among heavy drinkers of non-filtered coffee [31]. In addition,
the association was stronger during the first years of follow-up,
which indicates that coffee intake is more relevant with respect to
the acute rather than chronic processes related to coronary
disease.
Caffeine is metabolized by the polymorphic cytochrome P450
1A2 (CYP1A2) enzyme. Recently Cornelis and co-workers deter-
mined whether CYP1A2 genotype modifies the association
between intake of caffeinated coffee and the risk of nonfatal
myocardial infarction [32]. They found that intake of coffee was
associated with an increased risk of myocardial infarction only
among individuals with slow caffeine metabolism and suggested
that caffeine plays a role in this association.
These findings led us to consider novel explanations behind the
dose–response relationship between coffee consumption and CHD
incidence. Coffee and caffeine have been shown to stimulate
adrenomedullary secretion, resulting in raised levels of circulating
catecholamines, adrenaline in particular [10,33]. In a subgroup of
the present study population with urinary catecholamine excretion
Figure 1. Odds ratios of acute coronary events in 773 men initially free
from CHD by joint categories of coffee intake and COMT genotype;
predicted from a logistic model with age, smoking, family history of
CHD, plasma vitamin C concentration, systolic blood pressure, serum
HDL and LDL cholesterol concentration, and diabetes as covariates.
doi:10.1371/journal.pone.0000117.g001
Table 3. Distribution of acute coronary events in the study population during an average follow-up of 13 years, according to the
joint coffee intake–COMT genotype categories.*
..................................................................................................................................................
Daily coffee intake
0–375 mL 376–813 mL 814 mL and over
No. of events (%) No. of participants No. of events (%) No. of participants No. of events (%) No. of participants
COMT HH or LH 14 (9.3%) 151 27 (9.0%) 299 8 (8.2%) 97
COMT LL 8 (13.3%) 60 13 (9.9%) 131 8 (22.9%) 35
*HH, homozygous for high COMT activity allele; LH, heterozygous; and LL, homozygous for low COMT activity allele.
doi:10.1371/journal.pone.0000117.t003
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COMT, Coffee Intake and CHD
PLoS ONE | www.plosone.org 4 December 2006 | Issue 1 | e117measured at baseline, we also observed a marked increase in
adrenaline excretion and some increase in the excretion of
noradrenaline with increasing coffee intake. Increases in circulat-
ing catecholamine levels and cortisol are characteristic of the
response to stress, both psychological and physiological, and
caffeine has been shown to potentiate stress-related increases in
plasma adrenaline and cortisol concentrations, both in habitual
and light consumers [12]. Stress in turn is a recognized risk factor
for CHD. Furthermore, stress appears to be more strongly related
to the rapid and more transient processes (such as rupture of
atherosclerotic plaques with subsequent platelet activation,
thrombus formation, and vasospasm) that lead to acute coronary
syndromes rather than to the long-term atherosclerotic process
[34]. On the other hand, treatment with beta-adrenoceptor
blocking agents has been shown to effectively reduce the risk of
acute coronary syndromes during acute periods of stress, such as
surgical stress [35], which is characterized by elevated adrenaline
and cAMP levels [36].
Hence, we hypothesized that heavy intake of caffeine-contain-
ing coffee induces a ‘‘chemical stress’’ and that the effect of this
stress response on CHD incidence is more evident in those whose
catecholamine metabolism is slower than usual and the mechan-
isms of tolerance may be overwhelmed. The main enzyme
responsible for the metabolism of circulating catecholamines is
COMT [37]. COMT activity shows functional polymorphism
determined by the COMT gene: those who are homozygous for
the low activity allele (about 25% of a Caucasian population) have
only one-half to one-fourth of the enzyme activity of the other
genetic variants [38]. These differences in COMT activity by
genotype are likely to be more pronounced in heavy consumers of
coffee, because caffeic acid directly inhibits COMT activity [39]
and caffeine inhibits adenosine deaminase [40], resulting in
a shift in homocysteine metabolism to the direction of S-
adenosyl-homocysteine and consequent further inhibition of
COMT activity [41]. Our finding of a 2.2 fold increase in the
incidence of acute coronary events among heavy coffee drinkers in
the low-activity COMT category, compared with the other two
COMT categories, is highly compatible with this hypothesis.
Our study is limited by the small study cohort and the fact that
only 78 CHD events were observed during an average follow-up of
13 years, resulting in imprecise effect estimates reflected as wide
confidence intervals. Nevertheless, we were able to control for the
most important potential confounding factors and still the differ-
ence in CHD incidence between the COMT activity categories
among heavy coffee drinkers persisted. Residual confounding
alone is unlikely to explain the remaining excess incidence.
Another major limitation of our study is restriction of the study
population to men only. Female hormones may influence
catecholamine pharmacodynamics [42] and thus our findings
are not necessarily applicable to women.
In conclusion, we suggest that circulating catecholamines play
a role as mediators of the effect of heavy coffee intake on the risk of
CHD events. The elevated risk may be more pronounced in or
even restricted to those whose catecholamine metabolism is slower
than usual. Further research is required to confirm or refute our
hypothesis.
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